Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Jun 28 2017

Full Issue

Perspectives: A Drug Seen As Epitome Of Personalized Medicine Was Just Approved By FDA

Read recent commentaries about drug-cost issues.

Stat: Landmark FDA Approval Bolsters Personalized Medicine

Our understanding of cancer has been morphing from a tissue-specific disease — think lung cancer or breast cancer — to a disease characterized more by specific genes or biomarkers than by location. A recent FDA decision underscores that transition and further opens the door to personalized medicine. (Edward Abrahams, 6/21)

Morning Consult: Minority Communities Need Better Health Care, Not Counterfeit Drugs

According to the most recent report by the Robert Wood Johnson Foundation, Latinos and African-Americans have health outcomes that are 30 to 40 percent poorer than white Americans. ... That’s why policymaking in the health care sphere has to move in a direction that closes this health outcomes gap, and takes great care not to make these disparities even worse. ... We could take giant steps backward, however, if Congress moves ahead with the idea of permitting the importation of prescription medicines from other countries. If this happens, the United States government will actually be promoting the use of counterfeit and unsafe medications from China, Mexico, Pakistan and other parts of the world in which our Food and Drug Administration has zero oversight. (Garfield Clunie and Richard Williams, 6/23)

CNN: Why US Health Care Costs Defy Common Sense

When Jeffrey Kivi's rheumatologist changed affiliations from one hospital in New York City to another, less than 20 blocks uptown, the price his insurer paid for the outpatient infusion he got about every 6 weeks to control his arthritis jumped from $19,000 to over $100,000. Same drug; same dose -- though, Kivi noted, the pricier infusion room had free cookies, Wi-Fi and bottled water. (Elisabeth Rosenthal, 6/26)

Crain's Chicago Business: President Donald Trump And Prescription Drug Pricing

We are all focused on Republican efforts to repeal the Affordable Care Act and replace it with new policies that will result in millions of Americans paying more and getting less. But there is another health care issue that also needs attention: the future of prescription drug prices. (Jan Schakowsky, 6/26)

The Star-Ledger: Don't Just Cap Costs For Cancer Patients; Put The Squeeze On Big Pharma

A proposal to cap the out-of-pocket cost of drugs, which just passed the state Senate unanimously, sounds like a Godsend for patients. If you've got a rare form of leukemia or HIV/AIDS and need a specialty drug that costs tens of thousands of dollars, it can be. (6/27)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 22
  • Thursday, May 21
  • Wednesday, May 20
  • Tuesday, May 19
  • Monday, May 18
  • Friday, May 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF